Difference between revisions of "RhoA"

From MyMediaWiki
Jump to: navigation, search
(New page: {{Subst:infobox}})
 
m
 
(10 intermediate revisions by one other user not shown)
Line 1: Line 1:
 
 
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;"
 
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;"
! {{infobox header}}| '''{{PAGENAME}}'''  
+
! {infobox header}| '''{{PAGENAME}}'''  
 
|-
 
|-
| align="center" colspan="2" bgcolor="#ffffff" | [[Image:{{PAGENAME}}.png|200px|{{PAGENAME}}]]  
+
| align="center" colspan="2" bgcolor="#ffffff" | [[Image:RhoA.JPG|200px|{{PAGENAME}}]]  
 
|-
 
|-
 
| Substrate peptide name
 
| Substrate peptide name
Line 12: Line 11:
 
|-
 
|-
 
| Determination type
 
| Determination type
| In situ
+
| In situ/In vitro
 
|-
 
|-
 
| Source
 
| Source
Line 21: Line 20:
 
|-
 
|-
 
| Swissprot ID
 
| Swissprot ID
| [http://au.expasy.org/uniprot/P08865 P08865]
+
| [http://au.expasy.org/uniprot/P61586 P61586 ]
 
|-
 
|-
 
| Reactive glutamines
 
| Reactive glutamines
| [[Q41 (Actin)|Q41]]
+
| [[TG2 reactive residues (RhoA)|Q52, Q63, Q136]]
 
|-
 
|-
 
| Reactive lysines
 
| Reactive lysines
| Not determined yet
+
| -
 
|-
 
|-
 
| Substrate sequence
 
| Substrate sequence
| GRPRHQGVMVG
+
| EVDGK''Q''VELAL
 +
 
 +
WDTAG''Q''EDYDR
 +
 
 +
LAKMK''Q''EPVKP
 
|-
 
|-
 
| Structure
 
| Structure
| [http://www.rcsb.org/pdb/explore/explore.do?structureId=2BTF 2BTF]
+
| [http://www.rcsb.org/pdb/explore/explore.do?structureId=1A2B 1A2B]
 
|-
 
|-
 
| Surface accessibility
 
| Surface accessibility
| [http://gibk21.bse.kyutech.ac.jp/asaview/all/2btfA.pdf ASAView] pdf
+
| [http://gibk21.bse.kyutech.ac.jp/asaview/all/1a2b.pdf ASAView] pdf
 +
[http://gibk21.bse.kyutech.ac.jp/asaview/all/1a2b.txt ASAView] txt
 
|-
 
|-
 
| Disorder prediction
 
| Disorder prediction
Line 42: Line 46:
 
|-
 
|-
 
| Reference
 
| Reference
| [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=9252372&dopt=Abstract PMID:9252372]
+
| [http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=9593707&dopt=Abstract PMID:9593707]
 
|-
 
|-
 
| Notes
 
| Notes
|  
+
| Q63 is deamidated/transamidated by TG2
 +
 
 +
The transamidated protein has increased binding affinity to ROCK-2.
 +
 
 +
The deamidated form (by cytotoxic dermonecrotizing factor or BTX) has decreased GTPase activity.
 +
|-
 +
|Video
 +
|{{#ev:dailymotion|19dSThNNq2NLtkXZ8|300}}
 
|-
 
|-
| {{infobox header}} |  
+
| {infobox header} |  
 
|-
 
|-
 
|}
 
|}
  
 
[[Category:Tissue transglutaminase|*]]
 
[[Category:Tissue transglutaminase|*]]
 +
[[Category:Deamidase|*]]

Latest revision as of 11:54, 10 March 2015

RhoA
RhoA
Substrate peptide name RhoA
Synonyms -
Determination type In situ/In vitro
Source Homo sapiens
Subcellular localization Cytoskeleton
Swissprot ID P61586
Reactive glutamines Q52, Q63, Q136
Reactive lysines -
Substrate sequence EVDGKQVELAL

WDTAGQEDYDR

LAKMKQEPVKP

Structure 1A2B
Surface accessibility ASAView pdf

ASAView txt

Disorder prediction IUPred
Reference PMID:9593707
Notes Q63 is deamidated/transamidated by TG2

The transamidated protein has increased binding affinity to ROCK-2.

The deamidated form (by cytotoxic dermonecrotizing factor or BTX) has decreased GTPase activity.

Video 19dSThNNq2NLtkXZ8|300}}